ConductScience.org, home

Paper40453079

Strategies for CRISPR-based knock-ins in primary human B cells and lymphoma cell lines.

Lund S and 5 others. Front Immunol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Strategies for CRISPR-based knock-ins in primary human B cells and lymphoma cell lines. Papers, record 40453079. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40453079

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Strategies for CRISPR-based knock-ins in primary human B cells and lymphoma cell lines.
PubMed
Journal
Front Immunol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-06-09
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lund SSophie
2Gong CChun
3Yu XXin
4Staudt LMLouis M
5Hodson DJDaniel J
6Scheich SSebastian

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CRISPR-Cas SystemsMajor topic
Gene Knock-In TechniquesMajor topic
Gene EditingMajor topic
B-LymphocytesMajor topic
Lymphoma, Large B-Cell, DiffuseMajor topic
Humans
Cell Line, Tumor

Source PubMed

Download CSV of topics

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129713087Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med2018https://conductscience.org/library/papers/29713087PubMed
229259529Genome Editing: Past, Present, and Future.Yale J Biol Med2017https://conductscience.org/library/papers/29259529PubMed
333398341Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing.Nucleic Acids Res2021https://conductscience.org/library/papers/33398341PubMed
432289277A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.Cancer Cell2020https://conductscience.org/library/papers/32289277PubMed
521699444Romidepsin: a novel histone deacetylase inhibitor for cancer.Expert Opin Investig Drugs2011https://conductscience.org/library/papers/21699444PubMed
635658124BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.Cancer Discov2022https://conductscience.org/library/papers/35658124PubMed
726543202Quantitative nature of overexpression experiments.Mol Biol Cell2015https://conductscience.org/library/papers/26543202PubMed
831794945Metabolic control of B cell immune responses.Curr Opin Immunol2020https://conductscience.org/library/papers/31794945PubMed
937141112Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas.Cancer Discov2023https://conductscience.org/library/papers/37141112PubMed
1039535522Efficient CRISPR/Cas9 Knock-in Approaches for Manipulation of Endogenous Genes in Human B Lymphoma Cells.Curr Protoc2024https://conductscience.org/library/papers/39535522PubMed
1133657296Diffuse Large B-Cell Lymphoma.N Engl J Med2021https://conductscience.org/library/papers/33657296PubMed
1211131974Overview of vector design for mammalian gene expression.Mol Biotechnol2000https://conductscience.org/library/papers/11131974PubMed
1329925955A multiprotein supercomplex controlling oncogenic signalling in lymphoma.Nature2018https://conductscience.org/library/papers/29925955PubMed
1433005303CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy.Comput Struct Biotechnol J2020https://conductscience.org/library/papers/33005303PubMed
1529641966Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.N Engl J Med2018https://conductscience.org/library/papers/29641966PubMed
1617379808CRISPR provides acquired resistance against viruses in prokaryotes.Science2007https://conductscience.org/library/papers/17379808PubMed
1738473704Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches.Int J Mol Sci2024https://conductscience.org/library/papers/38473704PubMed
1837215153Strategies for precise gene edits in mammalian cells.Mol Ther Nucleic Acids2023https://conductscience.org/library/papers/37215153PubMed
1934456559Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing.Biologics2021https://conductscience.org/library/papers/34456559PubMed
2036171658CRISPR-Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing.Biochemistry (Mosc)2022https://conductscience.org/library/papers/36171658PubMed

See all 25 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40453079

GET https://conductscience.org/api/papers/v1/40453079/references?page=2